Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib in KRAS G12C mutant metastatic pancreatic cancer
NCT05634525Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adagrasib, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival at 1 year and Objective Response Rate. Planned start May 2023; status: withdrawn.
02
Drugs
adagrasib
Beyond the preview
Go deeper on NCT05634525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634525.